Table 2.
Results of clinical trials using immunotherapy with or without chemotherapy as neoadjuvant therapy for resectable NSCLC patients.
| Trial [Reference] |
Stage | Number of Patients Recruited | Drugs Used in Neoadjuvant Therapy | Primary Endpoint | MPR (%) |
|---|---|---|---|---|---|
| Forde et al. (NCT02259621) [79] |
Stages I-IIIA | 21 | Nivolumab (monotherapy) | Safety and feasibility | 45 |
| NEOSTAR (NCT03158129) [83] |
Stages IA-IIIA | 44 | Nivolumab or nivolumab + ipilimumab |
MPR | 24 in nivolumab group 50 in nivolumab + ipilimumab group |
| NADIM (NCT03081689) [87] |
Stages IIIA | 46 | Nivolumab + carboplatin + paclitaxel | 24-month PFS (77.1%) |
83 |
| Shu et al. (NCT02716038) [88] |
Stages II-IIIA | 30 | Atezolizumab + carboplatin + nab-paclitaxel |
MPR | 57 |
| LCMC3 (NCT02927301) [78,89] |
Stages IB-IIIB | 82 | Atezolizumab (monotherapy) | MPR | 18 |
| Ready et al. (NCT02818920) [89] |
Stages IB-IIIB | 25 | Pembrolizumab (monotherapy) | MPR | 28 |
| PRINCEPS (NCT02994576) [93] |
Stages IA (>2 cm)-IIIA | 30 | Atezolizumab (monotherapy) | Toxicity | Not available |
| Gao et al. (ChiCTR-OIC-17013726) [94] |
Stages IA-IIIB | 40 | Sintilimab (monotherapy) | MPR | 40.5 |
Abbreviations: MPR, major pathological response; PFS, progression-free survival.